Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis
Identifieur interne : 000168 ( Main/Corpus ); précédent : 000167; suivant : 000169Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis
Auteurs : Christopher G. Goetz ; Murat Emre ; Bruno DuboisSource :
- Annals of Neurology [ 0364-5134 ] ; 2008-12.
Abstract
Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92
Url:
DOI: 10.1002/ana.21455
Links to Exploration step
ISTEX:E0ECBC608C6DE11FD89FD9155F4587D64FF806B4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E0ECBC608C6DE11FD89FD9155F4587D64FF806B4</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21455</idno><idno type="url">https://api.istex.fr/document/E0ECBC608C6DE11FD89FD9155F4587D64FF806B4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000168</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S81">S81</biblScope><biblScope unit="page" to="S92">S92</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">E0ECBC608C6DE11FD89FD9155F4587D64FF806B4</idno><idno type="DOI">10.1002/ana.21455</idno><idno type="ArticleID">ANA21455</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</json:string></affiliations></json:item><json:item><name>Murat Emre MD</name><affiliations><json:string>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</json:string></affiliations></json:item><json:item><name>Bruno Dubois MD</name><affiliations><json:string>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item></author><articleId><json:string>ANA21455</json:string></articleId><language><json:string>eng</json:string></language><abstract>Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1843</abstractCharCount><pdfWordCount>8311</pdfWordCount><pdfCharCount>54773</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>254</abstractWordCount></qualityIndicators><title>Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title><genre><json:string>article</json:string></genre><host><volume>64</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>12</total><last>S92</last><first>S81</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S2</issue><subject><json:item><value>Clinical Issues</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/ana.21455</json:string></doi><id>E0ECBC608C6DE11FD89FD9155F4587D64FF806B4</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E0ECBC608C6DE11FD89FD9155F4587D64FF806B4/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E0ECBC608C6DE11FD89FD9155F4587D64FF806B4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E0ECBC608C6DE11FD89FD9155F4587D64FF806B4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). C.G.G. has received honoaria for consulting and serving on scientific advisory boards for BI, Allergan, Biogen, Ceregene, EMD Pharmaceuticals, Embryon, Impax Pharmaceuticals, I3 Research, Juvantia Pharmaceuticals, Kiowa Pharmaceuticals, GlaxoSmith Kline, Merck KgaA, Merck and Co, Neurim Pharmaceuticals, Novartis Pharmaceuticals, Ovation Pharmaceuticals, Oxford Biomedica, Schering‐Plough, Solstice Neurosciences, Solvay Pharmaceuticals, Synergy/Intec, and Teva Pharmaceuticals. M.E. has received honoraria for speaking at a symposia sponsored by BI. M.E. has also received honoraria for speaking for Novartis, Lundbeck, and Merck Serono. M.E. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Pfizer, Novartis Pharmaceuticals, Lundbeck, Teva Pharmaceuticals, Noscira, Merck Serono. M.E. has received reseach grants from Novartis and Lundbeck. B.D. has no financial relationships with BI to disclose. B.D. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Servier, Lundbeck, Pierre Fabre, Janssen Cilag, and Merck Serono.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Rush University Medical Center, Chicago, IL 60612</p></note><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</affiliation></author><author><persName><forename type="first">Murat</forename><surname>Emre</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</affiliation></author><author><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12"></date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S81">S81</biblScope><biblScope unit="page" to="S92">S92</biblScope></imprint></monogr><idno type="istex">E0ECBC608C6DE11FD89FD9155F4587D64FF806B4</idno><idno type="DOI">10.1002/ana.21455</idno><idno type="ArticleID">ANA21455</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Clinical Issues</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-03-04">Received</change><change when="2008-06-02">Registration</change><change when="2008-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E0ECBC608C6DE11FD89FD9155F4587D64FF806B4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="250"><doi origin="wiley" registered="yes">10.1002/ana.v64:2+</doi><titleGroup><title type="supplementTitle">Unresolved Issues in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="64">64</numbering><numbering type="journalIssue">S2</numbering><numbering type="supplement" number="2">2</numbering></numberingGroup><coverDate startDate="2008-12">December 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.21455</doi><idGroup><id type="unit" value="ANA21455"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Clinical Issues</title><title type="tocHeading1">Clinical Issues</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2008-03-04"></event><event type="manuscriptRevised" date="2008-05-29"></event><event type="manuscriptAccepted" date="2008-06-02"></event><event type="firstOnline" date="2009-01-06"></event><event type="publishedOnlineFinalForm" date="2009-01-06"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:FullText result:FullText" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S81</numbering><numbering type="pageLast">S92</numbering></numberingGroup><correspondenceTo>Rush University Medical Center, Chicago, IL 60612</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA21455.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="121"></count><count type="wordTotal" number="9183"></count></countGroup><titleGroup><title type="main" xml:lang="en">Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis<link href="#fn1"></link></title><title type="short" xml:lang="en">Parkinson's Disease Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName><contactDetails><email>cgoetz@rush.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Murat</givenNames><familyName>Emre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="TR" type="organization"><unparsedAffiliation>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). C.G.G. has received honoaria for consulting and serving on scientific advisory boards for BI, Allergan, Biogen, Ceregene, EMD Pharmaceuticals, Embryon, Impax Pharmaceuticals, I3 Research, Juvantia Pharmaceuticals, Kiowa Pharmaceuticals, GlaxoSmith Kline, Merck KgaA, Merck and Co, Neurim Pharmaceuticals, Novartis Pharmaceuticals, Ovation Pharmaceuticals, Oxford Biomedica, Schering‐Plough, Solstice Neurosciences, Solvay Pharmaceuticals, Synergy/Intec, and Teva Pharmaceuticals. M.E. has received honoraria for speaking at a symposia sponsored by BI. M.E. has also received honoraria for speaking for Novartis, Lundbeck, and Merck Serono. M.E. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Pfizer, Novartis Pharmaceuticals, Lundbeck, Teva Pharmaceuticals, Noscira, Merck Serono. M.E. has received reseach grants from Novartis and Lundbeck. B.D. has no financial relationships with BI to disclose. B.D. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Servier, Lundbeck, Pierre Fabre, Janssen Cilag, and Merck Serono.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Parkinson's Disease Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis</title></titleInfo><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL</affiliation><description>Correspondence: Rush University Medical Center, Chicago, IL 60612</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murat</namePart><namePart type="family">Emre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Istanbul Faculty of Medicine, Capa Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Institut National de la Sante et de la Recherche Médicale U610, Fédération de Neurologie, Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-12</dateIssued><dateCaptured encoding="w3cdtf">2008-03-04</dateCaptured><dateValid encoding="w3cdtf">2008-06-02</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">121</extent><extent unit="words">9183</extent></physicalDescription><abstract lang="en">Cognitive impairment is common in Parkinson's disease (PD) and involves attentional, executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered in PD than in age‐matched control populations, and whereas operational definitions of Alzheimer's disease and dementia with Lewy bodies have been developed, Parkinson's disease dementia (PD‐D) has remained undefined. The Movement Disorder Society developed a task force to define and develop diagnostic guidelines for PD‐D. This effort was based on existing descriptive studies with special emphasis on drawing distinction among Alzheimer's disease, dementia with Lewy bodies and PD‐related cognitive impairment without dementia whenever possible. The second goal was to provide practical diagnostic procedures to diagnose PD‐D. This effort emphasized available bedside tools that do not require neuropsychological expertise to administer or interpret. This work recently has been completed, and two primary articles have been published. The suggested clinical diagnostic criteria for PD‐D involve four domains and are anchored in core features, associated clinical features, features that make the diagnosis uncertain, and features that are not compatible with the diagnosis of PD‐D. When all four criteria are satisfactorily met, probable PD‐D is designated; when the first and last criteria are met, but clinical characteristics are atypical or uncertainty factors exist, possible PD‐D is designated. Whereas these definitions are operative and subject to change based on future data, they are based on widely available tests. The inclusion criteria can be applied internationally and in multicenter research on treatment interventions, clinicopathological correlations, and studies of cognitive and other nonmotor elements of PD. Ann Neurol 2008;64 (suppl):S81–S92</abstract><note type="content">*Potential conflicts of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). C.G.G. has received honoaria for consulting and serving on scientific advisory boards for BI, Allergan, Biogen, Ceregene, EMD Pharmaceuticals, Embryon, Impax Pharmaceuticals, I3 Research, Juvantia Pharmaceuticals, Kiowa Pharmaceuticals, GlaxoSmith Kline, Merck KgaA, Merck and Co, Neurim Pharmaceuticals, Novartis Pharmaceuticals, Ovation Pharmaceuticals, Oxford Biomedica, Schering‐Plough, Solstice Neurosciences, Solvay Pharmaceuticals, Synergy/Intec, and Teva Pharmaceuticals. M.E. has received honoraria for speaking at a symposia sponsored by BI. M.E. has also received honoraria for speaking for Novartis, Lundbeck, and Merck Serono. M.E. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Pfizer, Novartis Pharmaceuticals, Lundbeck, Teva Pharmaceuticals, Noscira, Merck Serono. M.E. has received reseach grants from Novartis and Lundbeck. B.D. has no financial relationships with BI to disclose. B.D. has received honoraria for consulting and serving on scientific advisory boards for Eisai, Servier, Lundbeck, Pierre Fabre, Janssen Cilag, and Merck Serono.</note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Clinical Issues</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>2</number></detail><extent unit="pages"><start>S81</start><end>S92</end><total>12</total></extent></part></relatedItem><identifier type="istex">E0ECBC608C6DE11FD89FD9155F4587D64FF806B4</identifier><identifier type="DOI">10.1002/ana.21455</identifier><identifier type="ArticleID">ANA21455</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000168 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000168 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E0ECBC608C6DE11FD89FD9155F4587D64FF806B4
|texte= Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis
}}
| This area was generated with Dilib version V0.6.23. |  |